(9H-fluoren-9-yl)methyl (hydroxymethyl)carbamate | 1227098-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (9H-fluoren-9-yl)methyl (hydroxymethyl)carbamate
• 英文别名: hydroxymethyl-carbamic acid 9H-fluoren-9-ylmethyl ester；9H-fluoren-9-ylmethyl N-(hydroxymethyl)carbamate
• CAS: 1227098-32-9
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.3
• InChiKey: LLHUGMUCWNAQMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (9H-fluoren-9-yl)methyl (hydroxymethyl)carbamate 在 三甲基氯硅烷 作用下， 以 氘代氯仿 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 chloromethylcarbamic acid 9H-fluoren-9-ylmethyl ester
  参考文献：
  名称：

  使用三甲基甲硅烷基卤化物活化Fmoc保护的N，O-缩醛的机理和合成研究

  摘要：

  Fmoc保护的N，O-缩醛的三甲基甲硅烷基卤化物活化产生能够有效地添加到多种烯胺中的反应性中间体。NMR研究提供了证据，表明在溶液中形成了稳定的氨基甲酸卤甲基酯中间体。在宽范围的烯胺亲核试剂上都获得了良好的收率，包括环和非环状的酮衍生和醛衍生的烯胺。初步研究表明，烯胺的添加是通过协调一致的S N 2型机制发生的。

  DOI：

  10.1021/ol100494z
• 作为产物：
  描述：

  ((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl acetate 在 aluminum oxide 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以49%的产率得到(9H-fluoren-9-yl)methyl (hydroxymethyl)carbamate
  参考文献：
  名称：

  使用三甲基甲硅烷基卤化物活化Fmoc保护的N，O-缩醛的机理和合成研究

  摘要：

  Fmoc保护的N，O-缩醛的三甲基甲硅烷基卤化物活化产生能够有效地添加到多种烯胺中的反应性中间体。NMR研究提供了证据，表明在溶液中形成了稳定的氨基甲酸卤甲基酯中间体。在宽范围的烯胺亲核试剂上都获得了良好的收率，包括环和非环状的酮衍生和醛衍生的烯胺。初步研究表明，烯胺的添加是通过协调一致的S N 2型机制发生的。

  DOI：

  10.1021/ol100494z

文献信息

• SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY
  申请人：Powell Michael J

  公开号：US20190330621A1

  公开（公告）日：2019-10-31

  The invention provides xenonucleic acids and synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.

  该发明提供了xenonucleic acids和合成嵌合xenonucleic acid guide RNA；s(XNA-gRNA)，用于增强crispr介导的基因组编辑效率。该发明还提供了诱导CRISPR/Cas基因编辑/调控（例如基因组编辑或基因表达）靶向核酸（例如靶向DNA或靶向RNA）在细胞中的方法和组合物。这些方法包括使用已经经过化学修饰的xeno核酸的单导RNA（sgRNAs），这些核酸增强了原代细胞中靶向核酸的基因调控，用于体外治疗或用于体内治疗中的受体细胞。此外，本文提供了通过向受体注射已经经过化学修饰的xeno核酸的足够数量的sgRNA来预防或治疗受体的遗传疾病的方法，以纠正与该遗传疾病相关的靶基因的突变。
• PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES
  申请人：PROLYNX LLC

  公开号：US20140296476A1

  公开（公告）日：2014-10-02

  The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.

  本发明提供了一种允许体内控制和延长药物释放的方法和组合物。这些化合物可以是具有可调节释放速率的前药，或者是药物与展现可调控释放速率的大分子的结合物。
• DNA mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling
  申请人：Powell Michael J

  公开号：US11208689B2

  公开（公告）日：2021-12-28

  The invention relates to a method for enriching a target polynucleotide sequence containing a genetic variation said method comprising: (a) providing two primers targeted to said target polynucleotide sequence; (b) providing a target specific xenonucleic acid clamp oligomer specific for a wildtype polynucleotide sequence; (c) generating multiple amplicons using PCR under specific temperature cycling conditions; and (d) detecting said amplicons. We introduce a novel molecule, Xenonucleic Acid (XNA) for the NGS library preparation. XNA is able to selectively suppress amplification of DNA with wild type alleles and amplify DNA containing mutant alleles. Mutants with low allelic frequency will be easily detectable without deep sequencing after enrichment by adding XNA in multiplex PCR. The 17 actionable mutants related to lung or colorectal cancer diseases at different variant allelic frequency (VAF) % were investigated. Clinical sensitivity is significantly improved with XNA in various types of samples.

  本发明涉及一种富集含有遗传变异的目标多核苷酸序列的方法，所述方法包括：(a) 提供针对所述目标多核苷酸序列的两个引物；(b) 提供针对野生型多核苷酸序列的目标特异性异种核酸钳夹寡聚体；(c) 在特定温度循环条件下使用 PCR 生成多个扩增子；以及 (d) 检测所述扩增子。我们为 NGS 文库制备引入了一种新型分子--Xenonucleic Acid（XNA）。XNA 能够选择性地抑制野生型等位基因 DNA 的扩增，而扩增含有突变等位基因的 DNA。在多重 PCR 中加入 XNA 进行富集后，等位基因频率较低的突变体无需深度测序即可轻松检测到。我们研究了与肺癌或结直肠癌疾病相关的 17 种可操作突变体，其变异等位基因频率（VAF）各不相同。在各种类型的样本中，使用 XNA 可明显提高临床灵敏度。
• DNA MUTATION DETECTION EMPLOYING ENRICHMENT OF MUTANT POLYNUCLEOTIDE SEQUENCES AND MINIMALLY INVASIVE SAMPLING
  申请人：Powell Michael J

  公开号：US20190330692A1

  公开（公告）日：2019-10-31

  The invention relates to a method for enriching a target polynucleotide sequence containing a genetic variation said method comprising: (a) providing two primers targeted to said target polynucleotide sequence; (b) providing a target specific xenonucleic acid clamp oligomer specific for a wildtype polynucleotide sequence; (c) generating multiple amplicons using PCR under specific temperature cycling conditions; and (d) detecting said amplicons. We introduce a novel molecule, Xenonucleic Acid (XNA) for the NGS library preparation. XNA is able to selectively suppress amplification of DNA with wild type alleles and amplify DNA containing mutant alleles. Mutants with low allelic frequency will be easily detectable without deep sequencing after enrichment by adding XNA in multiplex PCR. The 17 actionable mutants related to lung or colorectal cancer diseases at different variant allelic frequency (VAF)% were investigated. Clinical sensitivity is significantly improved with XNA in various types of samples.
• XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION
  申请人：Sha Michael Y

  公开号：US20220025453A1

  公开（公告）日：2022-01-27

  The invention provides a multiplex method for enriching a plurality of target polynucleotide sequences containing genetic mutations associated with lung cancer comprising: (a) providing a biological sample; (b) isolating DNA from said sample; said DNA including said plurality of target polynucleotide sequences containing genetic mutations; (c) providing a plurality of primer probes targeted to said target polynucleotide sequences said primer probes allowing formation of a PCR product; (d) providing a plurality of target specific xenonucleic acid clamps oligomer probes specific for wildtype polynucleotide sequences; so that during the qPCR process only mutant templates are amplified: (e) admixing the plurality of primer probes and the plurality of xenonucleic clamping probes with the target nucleic acid sample; (f) performing a PCR amplification process in reaction solution under hybridization conditions thereby generating multiple amplicons; and (g) detecting said amplicons and wherein said xenonucleic acid clamps have aza-aza, thio-aza and oxy-aza chemical functionality.